ALG6-CDG — alpha-1,3-glucosyltransferase deficiency (OMIM #603147), the third most common congenital disorder of glycosylation (CDG Ic), caused by biallelic pathogenic variants in ALG6 (encoding dolichyl-P-Glc:Man9GlcNAc2-PP-dolichol glucosyltransferase, the endoplasmic reticulum-resident enzyme that adds the first of three terminal glucose residues to the Man9GlcNAc2-PP-dolichol lipid-linked oligosaccharide precursor in the stepwise assembly of the 14-sugar dolichol-linked oligosaccharide Glc3Man9GlcNAc2 that is transferred en bloc by the oligosaccharyltransferase complex to asparagine residues on nascent glycoproteins) — with enzymatic deficiency producing a selective failure to add the first glucose to the glycan precursor, resulting in transfer of the underglucosylated Man9GlcNAc2 to protein glycosylation sites rather than the fully assembled Glc3Man9GlcNAc2, with the underglucosylated glycan subsequently failing to engage properly with the calnexin/calreticulin quality control cycle in the endoplasmic reticulum (which requires glucose recognition for glycoprotein folding assistance and ER quality control), producing widespread misfolding of glycoproteins that depend on the calnexin/calreticulin pathway for proper tertiary structure acquisition and causing the clinical phenotype primarily through ER stress, misfolded glycoprotein accumulation, and the unfolded protein response — manifests with a predominant neurological phenotype without the severe cerebellar hypoplasia that characterizes PMM2-CDG, including intellectual disability of moderate to severe degree, hypotonia (generalized axial and appendicular hypotonia from infancy), ataxia (cerebellar-type gait and limb ataxia without the structural cerebellar malformation of PMM2-CDG — reflecting functional cerebellar dysfunction from glycoprotein hypoglycosylation rather than structural developmental cerebellar loss), seizures (epilepsy present in approximately 50% of patients, including focal and generalized seizure types), strabismus, and in many patients a relatively preserved brain MRI without the cerebellar hypoplasia or cortical atrophy of the most severe CDG syndromes — with coagulopathy (elevated INR, reduced factor XI, reduced antithrombin, reduced protein C) reflecting the hypoglycosylation of coagulation glycoproteins, and liver disease (elevated transaminases, hepatomegaly in a subset) as additional multi-system features. ALG6-CDG is biochemically characterized by the Type I CDG transferrin pattern on isoelectric focusing or mass spectrometry (identical to PMM2-CDG in transferrin pattern — requiring enzymatic and molecular follow-up to distinguish), reduced ALG6 enzyme activity or abnormal glucosyltransferase I assay in fibroblasts, and biallelic pathogenic ALG6 variants — with the p.Ala333Val founder variant in the Irish-American population, the most common ALG6-CDG variant worldwide, accounting for the majority of identified ALG6-CDG alleles in Western patient series. The estimated prevalence of ALG6-CDG is substantially lower than PMM2-CDG, with approximately 50 cases reported worldwide, representing a disease where monitoring platform reliability is directly linked to the seizure monitoring urgency, the coagulopathy management complexity, the neurodevelopmental surveillance obligations, and the multi-system hepatic and ophthalmological monitoring demands of a CDG syndrome with a distinct neurodevelopmental trajectory without the structural cerebellar malformation that defines the most prevalent CDG.
ALG6-CDG technology platforms — encompassing the transferrin isoelectric focusing and mass spectrometry platforms establishing the CDG Type I biochemical diagnosis (identical transferrin pattern to PMM2-CDG requiring follow-up enzyme and molecular testing to distinguish), the ALG6 enzyme activity assay platforms and glucosyltransferase I functional assay systems in fibroblasts, the molecular genetics platforms performing ALG6 sequencing (including detection of the p.Ala333Val founder variant) and deletion/duplication analysis, the coagulation monitoring platforms measuring factor XI, antithrombin, protein C, protein S, and INR, the epilepsy monitoring platforms including EEG (routine and prolonged video-EEG) and anti-epileptic drug level monitoring, the neuroimaging platforms performing brain MRI (characteristically showing less severe changes than PMM2-CDG, but with cortical malformations and white matter changes in severe cases), the neurodevelopmental assessment platforms tracking cognitive trajectory, adaptive behavior, and motor development, the hepatic function monitoring platforms, the ophthalmological assessment platforms for strabismus and retinal disease, the physical and occupational therapy coordination platforms, and CDG natural history registry systems — must maintain the availability and performance standards required by the seizure monitoring urgency, coagulopathy management complexity, neurodevelopmental surveillance obligations, and multi-system monitoring demands of ALG6-CDG. This guide explains why ALG6-CDG tech platforms need dedicated monitoring, what components to monitor, and how to build a monitoring strategy matched to the seizure monitoring urgency, coagulopathy management complexity, neurodevelopmental surveillance obligations, and multi-system monitoring demands of ALG6-CDG.
Why ALG6-CDG Tech Platforms Require Specialized Monitoring Attention
ALG6-CDG management presents monitoring challenges shaped by the seizure monitoring urgency, the coagulopathy management complexity, the neurodevelopmental surveillance obligations, and the multi-system hepatic, ophthalmological, and coagulation monitoring demands of a CDG syndrome with a neurodevelopmental phenotype that differs importantly from the most common CDG syndromes: the seizure monitoring urgency — epilepsy is present in approximately 50% of ALG6-CDG patients, including focal and generalized seizure types; seizure onset frequently occurs in infancy or early childhood; seizure management in ALG6-CDG requires anti-epileptic drug monitoring with drug level surveillance, seizure frequency tracking, and EEG characterization of the epilepsy syndrome; status epilepticus is a risk in uncontrolled epilepsy; platform failures disrupting EEG access during acute seizure escalation delay the epilepsy characterization that determines the most appropriate anti-epileptic drug selection; the coagulopathy management complexity — as in other CDG syndromes, coagulopathy from hypoglycosylation of coagulation glycoproteins creates concurrent procoagulant and anticoagulant deficiency with hemorrhagic and thrombotic risk; the neurodevelopmental surveillance obligation — intellectual disability of moderate to severe degree requires longitudinal neurodevelopmental assessment for educational placement, supported living, and quality-of-life monitoring; the ataxia without cerebellar hypoplasia distinguishes ALG6-CDG from PMM2-CDG and requires cerebellar function monitoring independent of structural neuroimaging; and the multi-system monitoring demand — hypotonia, strabismus, liver disease, and potential peripheral neuropathy require parallel surveillance across specialties.
EEG and epilepsy monitoring platforms are the primary life-safety monitoring tools for the approximately 50% of ALG6-CDG patients with epilepsy — failures during acute seizure escalation or status epilepticus delay the epilepsy characterization, anti-epileptic drug selection, and treatment monitoring that are the primary interventions protecting against seizure-related brain injury and sudden unexpected death in epilepsy. ALG6-CDG epilepsy encompasses focal and generalized seizure types; the EEG background reflects the degree of cortical glycoprotein dysfunction; anti-epileptic drug selection in ALG6-CDG follows general epilepsy treatment principles but must consider the coagulopathy (valproate and phenytoin may worsen coagulopathy), hepatic disease (hepatotoxic drug avoidance), and metabolic context; platform failures disrupting EEG during acute seizure escalation delay seizure type characterization that determines whether the treating neurologist escalates to status epilepticus treatment or adjusts anti-epileptic drug combination. Monitor at 1-minute intervals during clinical hours. Alert immediately.
Transferrin CDG analysis platforms are the diagnostic gateway for ALG6-CDG — the Type I CDG transferrin pattern distinguishes ALG6-CDG (and all Type I CDG syndromes) from structural brain malformations, chromosomal disorders, and other causes of intellectual disability and hypotonia, directing the enzyme activity and molecular testing cascade that establishes the specific CDG diagnosis. The Type I CDG transferrin pattern in ALG6-CDG is biochemically identical to PMM2-CDG on transferrin analysis, requiring ALG6 glucosyltransferase enzyme activity and molecular testing to distinguish; a platform failure disrupting transferrin CDG analysis during the diagnostic evaluation of a child with unexplained intellectual disability, hypotonia, and seizures delays the CDG biochemical diagnosis that redirects the workup from chromosomal microarray and intellectual disability genetic panel testing to metabolic CDG enzyme and molecular testing. Monitor at 1-minute intervals during laboratory hours. Alert immediately.
Coagulation monitoring platforms are critical in ALG6-CDG for management of the paradoxical coagulopathy — simultaneous procoagulant and anticoagulant glycoprotein deficiency creating hemorrhagic and thrombotic risk, with additional complexity introduced by the interaction between coagulopathy and commonly used anti-epileptic drugs. Factor XI, antithrombin, protein C, and protein S are all reduced in ALG6-CDG due to hypoglycosylation; valproate — a commonly used broad-spectrum anti-epileptic drug — inhibits platelet function and may exacerbate hemorrhagic risk in patients with underlying coagulopathy; phenytoin displaces protein C and protein S from plasma proteins; platform failures disrupting coagulation monitoring during anti-epileptic drug initiation or dose adjustment prevent detection of drug-coagulopathy interactions that may increase hemorrhagic risk. Monitor at 1-minute intervals during clinical and laboratory hours. Alert immediately.
What to Monitor on a ALG6-CDG Care Tech Platform
Transferrin CDG Analysis and Glucosyltransferase Biochemistry
Monitor transferrin isoelectric focusing and mass spectrometry records (transferrin isoelectric focusing at diagnosis — the Type I CDG pattern establishing CDG biochemistry and directing the ALG6 enzyme and molecular testing cascade; transferrin mass spectrometry for precise glycoform quantification; the biochemically indistinguishable Type I CDG transferrin pattern shared between ALG6-CDG, PMM2-CDG, and all other Type I CDG syndromes — requiring enzyme activity and molecular follow-up to establish the specific diagnosis; serial transferrin CDG analysis during follow-up — ALG6-CDG has no specific treatment capable of normalizing glycosylation, so transferrin monitoring serves as a disease stability biomarker rather than a therapeutic response endpoint; the impact of concurrent conditions — iron deficiency, hemolysis, liver disease, or pregnancy on transferrin pattern interpretation), ALG6 glucosyltransferase enzyme activity records (glucosyltransferase I enzyme assay in fibroblasts measuring the addition of the first glucose to the Man9GlcNAc2-PP-dolichol lipid-linked oligosaccharide precursor; the glucosyltransferase I functional assay is the primary enzyme confirmation test for ALG6-CDG; reduced glucosyltransferase I activity below 20% of normal in patient fibroblasts; the requirement for skin fibroblast culture (approximately 4–6 weeks) for enzyme assay — unlike PMM2 enzyme activity in leukocytes; enzyme activity correlation with clinical severity — limited in ALG6-CDG), and CDG-related glycan biomarker records (total N-glycan profiling in plasma or dried blood spot — detection of Man9GlcNAc2 accumulation with reduced Glc3Man9GlcNAc2; mass spectrometry-based CDG glycan panels; dolichol-linked oligosaccharide profiling in fibroblasts; glycosylation-sensitive protein panels) — at a 1-minute interval during laboratory hours. Alert immediately.
Molecular Genetics — ALG6 Variant Identification and Family Cascade
Monitor ALG6 gene sequencing and deletion/duplication records (comprehensive ALG6 gene sequencing — the p.Ala333Val founder variant in the Irish-American population is the most common ALG6-CDG variant worldwide; the p.Ala333Val variant accounting for approximately 70–80% of ALG6 alleles in Western patient series; second allele identification — compound heterozygotes are common outside the Irish-American founder population; ALG6 coding sequence and splice site variant analysis; large deletion/duplication analysis by MLPA; variant classification by ACMG criteria; genotype-phenotype correlation in ALG6-CDG — limited by small patient numbers, but homozygous p.Ala333Val genotype produces the classic ALG6-CDG phenotype; compound heterozygotes with more severe second alleles may have more severe presentations), family cascade evaluation records (autosomal recessive inheritance with 25% sibling recurrence risk; parental carrier confirmation — the Irish-American founder effect means carrier frequency may be elevated in Irish-American families; at-risk sibling evaluation with transferrin CDG analysis and ALG6 molecular testing; presymptomatic newborn diagnosis enabling early developmental intervention; genetic counseling for extended family cascade in founder effect populations), and prenatal and preimplantation genetic testing records (prenatal molecular testing for known familial ALG6 variants; the p.Ala333Val founder variant allowing targeted carrier and prenatal testing in Irish-American families; preimplantation genetic testing planning; reproductive counseling records) — at a 1-minute interval during laboratory hours. Alert immediately.
Epilepsy Monitoring and Anti-Epileptic Drug Management
Monitor EEG records (routine EEG at epilepsy diagnosis and for epilepsy characterization — focal vs. generalized, EEG background rhythm, epileptiform discharge location and morphology; prolonged ambulatory EEG for seizure frequency quantification; video-EEG telemetry for seizure semiology documentation and focal onset characterization; EEG background changes tracking cortical dysfunction burden; interictal EEG for treatment response monitoring; EEG during acute seizure escalation and status epilepticus management; the EEG background in ALG6-CDG reflecting the degree of cortical glycoprotein dysfunction — typically showing diffuse background slowing with superimposed focal or generalized epileptiform activity in affected patients), seizure frequency and type records (seizure diary documentation — frequency, duration, semiology, postictal features; focal seizure characterization — the predominant seizure type in many ALG6-CDG patients; generalized tonic-clonic seizure frequency; absence and myoclonic seizure documentation in patients with generalized epilepsy; seizure breakthrough events during intercurrent illness or sleep deprivation; SUDEP risk assessment records), and anti-epileptic drug records (anti-epileptic drug selection — avoidance of valproate or cautious use with coagulation monitoring given platelet function effects; levetiracetam, lamotrigine, and lacosamide as first-line agents in many ALG6-CDG patients; drug level monitoring records for anti-epileptic drugs with narrow therapeutic windows — phenytoin, phenobarbital, carbamazepine; drug-drug interaction monitoring; hepatic function monitoring during hepatotoxic anti-epileptic drug use — carbamazepine, oxcarbazepine, phenytoin; ketogenic diet records in drug-refractory epilepsy; vagal nerve stimulator implant and programming records; ketogenic diet monitoring — glucose and ketone levels, lipid panel, acid-base status) — at a 1-minute interval during clinical hours. Alert immediately.
Coagulation and Thromboembolism Management
Monitor coagulation factor records (factor XI activity — reduced due to hypoglycosylation; antithrombin activity — reduced, contributing to thrombotic risk; protein C and protein S activities — reduced; fibrinogen — may be structurally abnormal; PT/INR and aPTT for functional coagulation assessment; platelet count and function in patients receiving valproate; coagulation factor trends during anti-epileptic drug initiation and dose adjustment; the paradoxical ALG6-CDG coagulopathy — concurrent procoagulant deficiency increasing hemorrhagic risk and anticoagulant deficiency increasing thrombotic risk; coagulation monitoring frequency during anti-epileptic drug changes), thromboembolism records (venous thromboembolism documentation; arterial events; anticoagulation management records for confirmed thromboembolism in the complex coagulopathy context; hemorrhagic event documentation — mucosal, soft tissue, central nervous system hemorrhage; surgical planning records requiring hematology input for perioperative coagulopathy management), and anti-epileptic drug-coagulopathy interaction records (valproate platelet function effects with underlying coagulopathy; phenytoin effects on protein C and S plasma binding; carbamazepine and enzyme induction effects; drug monitoring records in the context of established coagulopathy) — at a 1-minute interval during clinical and laboratory hours. Alert immediately.
Neuroimaging and Neurodevelopmental Assessment
Monitor brain MRI records (brain MRI at diagnosis — characteristically less severe than PMM2-CDG; brain MRI may be normal or show mild white matter changes, mild cortical atrophy without the marked cerebellar hypoplasia of PMM2-CDG, though cerebellar vermis hypoplasia is reported in some patients; MRI characterization of white matter signal changes — periventricular white matter T2/FLAIR changes; cortical malformation assessment — polymicrogyria and pachygyria reported in a minority of ALG6-CDG patients with severe presentations; serial MRI for progressive cortical atrophy tracking; diffusion-weighted MRI during acute neurological events; MR spectroscopy for metabolite profiling; the diagnostic importance of brain MRI without cerebellar hypoplasia in ALG6-CDG — the normal or near-normal structural MRI in a child with intellectual disability, hypotonia, and Type I CDG transferrin pattern should prompt ALG6 rather than PMM2 enzyme and molecular testing), neurodevelopmental assessment records (developmental milestones from infancy — motor, cognitive, language; Bayley Scales of Infant and Toddler Development; IQ and cognitive function from school age — moderate to severe intellectual disability in the majority; adaptive behavior — Vineland Adaptive Behavior Scales; ataxia assessment — cerebellar function assessment without structural cerebellar malformation, distinguishing ALG6-CDG from PMM2-CDG; language and communication assessment; educational placement and IEP records; transition planning for adulthood; adult adaptive function and supported living records), and motor assessment records (hypotonia quantification from infancy; motor milestone delays; physiotherapy assessment records; occupational therapy records; ataxia severity rating; peripheral neuropathy assessment — nerve conduction studies in patients with suspected sensorimotor neuropathy; wheelchair and adaptive equipment records) — at a 1-minute interval during clinical hours. Alert immediately.
Hepatic and Ophthalmological Monitoring
Monitor hepatic function records (ALT and AST — elevated in a subset of patients, reflecting hepatic glycoprotein dysfunction; GGT; albumin for synthetic function; total protein; bilirubin; INR for synthetic function; hepatic ultrasound for hepatomegaly documentation; serial hepatic function monitoring — liver disease in ALG6-CDG is typically less severe than in PMM2-CDG or MPI-CDG but requires surveillance; growth and nutritional adequacy monitoring in patients with hepatic disease), ophthalmological assessment records (strabismus — common in ALG6-CDG; orthoptic assessment and strabismus surgical records; visual acuity monitoring; fundoscopic examination for retinal disease; nystagmus documentation; ophthalmological follow-up frequency in patients with strabismus), and feeding and growth records (feeding difficulties in infancy — hypotonia contributing to poor oral feeding; gastrostomy tube placement records; caloric intake assessment; growth anthropometrics; swallowing assessment; dysphagia management; nutritional supplementation; speech-language pathology records for feeding and communication) — at a 1-minute interval during clinical hours. Alert immediately.
Authentication and Clinical Identity
Monitor authentication at 1-minute intervals, 24/7. ALG6-CDG management coordinates across metabolic medicine (transferrin CDG analysis, ALG6 enzyme activity, CDG biomarker monitoring), molecular genetics (ALG6 sequencing, family cascade, prenatal testing), pediatric and adult neurology (epilepsy management, EEG monitoring, ataxia management, white matter disease follow-up), neurophysiology (routine and video-EEG telemetry), hematology (coagulopathy management, anti-epileptic drug-coagulopathy interaction monitoring), hepatology (liver function surveillance), ophthalmology (strabismus management, retinal surveillance), dietetics (nutritional support, ketogenic diet management in drug-refractory epilepsy), physical and occupational therapy (hypotonia and ataxia management), speech-language pathology (communication and dysphagia), neurodevelopmental assessment services (cognitive trajectory, educational planning), and CDG patient registry coordination — authentication failures block the integrated multi-platform care coordination that the seizure monitoring urgency, coagulopathy management complexity, neurodevelopmental surveillance obligations, and multi-system monitoring demands require across ALG6-CDG.
SSL Certificates
Monitor SSL certificate expiry across all transferrin CDG analysis platforms, ALG6 glucosyltransferase enzyme assay systems, molecular genetics platforms, EEG and video-EEG telemetry systems, anti-epileptic drug level monitoring platforms, coagulation monitoring platforms, neuroimaging systems, neurodevelopmental assessment platforms, hepatic function laboratory systems, ophthalmological assessment platforms, ketogenic diet monitoring systems, and ALG6-CDG registry systems. Certificate errors disrupt the integrated multi-platform care infrastructure that ALG6-CDG management requires across the seizure monitoring urgency, coagulopathy management complexity, neurodevelopmental surveillance obligations, and multi-system monitoring demands.
HIPAA and Rare Genetic Disease Patient Privacy Considerations
ALG6-CDG technology platforms handle highly sensitive PHI encompassing ALG6 molecular testing results (biallelic variants identifying both parents as obligate carriers with 25% recurrence risk per pregnancy; the p.Ala333Val Irish-American founder variant identification with population-specific carrier frequency implications), transferrin CDG isoform records establishing the CDG biochemical diagnosis, EEG records documenting epilepsy syndrome characterization (with implications for driving, employment, and childcare regulations under state epilepsy disclosure laws), anti-epileptic drug records and drug level monitoring documentation (with implications for health and life insurance underwriting and professional licensing), intellectual disability severity documentation from neurodevelopmental assessments (with implications for guardianship proceedings, supported living placements, disability benefit determinations, and educational resource allocation across a lifetime), coagulation factor deficiency records (antithrombin, protein C, protein S deficiency with implications for surgical planning and anticoagulation management), brain MRI records (white matter changes, cortical malformations, and progressive atrophy with long-term functional prognosis implications), strabismus surgical records and ophthalmological assessments, and hepatic function records.
The extreme rarity of ALG6-CDG — approximately 50 cases reported worldwide — combined with the Irish-American p.Ala333Val founder variant creates a situation where clinical disclosure of the diagnosis could re-identify a patient within a small, closely networked rare disease community. Epilepsy disclosure laws in many jurisdictions impose mandatory reporting obligations on physicians when patients with epilepsy hold commercial driving licenses, creating a specific tension between clinical documentation accuracy and the statutory reporting obligations that apply to ALG6-CDG patients with active seizures.
Alerting Strategy for ALG6-CDG Tech Platforms
Immediate clinical-hours alerting for EEG and epilepsy monitoring platforms: EEG and video-EEG platforms are the primary safety monitoring tools for the approximately 50% of ALG6-CDG patients with epilepsy — failures during acute seizure escalation delay epilepsy characterization and anti-epileptic drug selection decisions that protect against status epilepticus and SUDEP risk.
Immediate laboratory-hours alerting for transferrin CDG analysis and ALG6 enzyme assay platforms: Transferrin isoelectric focusing and mass spectrometry platforms require immediate alerting during laboratory hours — the Type I CDG pattern is the gateway diagnostic step for all Type I CDG syndromes including ALG6-CDG, directing the ALG6 glucosyltransferase enzyme activity and molecular testing cascade.
Immediate clinical-hours alerting for coagulation monitoring platforms: Coagulation factor monitoring platforms require immediate alerting during clinical hours — the ALG6-CDG paradoxical coagulopathy creates concurrent hemorrhagic and thrombotic risk, with additional complexity from anti-epileptic drug interactions with coagulation factor function.
Immediate clinical-hours alerting for anti-epileptic drug level monitoring platforms: Anti-epileptic drug level monitoring platforms require immediate alerting during clinical hours for therapeutic drug level assessment during dose titration, breakthrough seizure evaluation, and drug toxicity monitoring.
Immediate clinical-hours alerting for neuroimaging platforms: Brain MRI platforms require immediate alerting during clinical hours for white matter and cortical disease characterization, serial atrophy tracking, and acute event evaluation in patients with epilepsy and coagulopathy.
Immediate laboratory-hours alerting for hepatic function platforms: Hepatic function monitoring platforms require immediate alerting during laboratory hours for liver disease surveillance and hepatotoxic anti-epileptic drug safety monitoring.
Sustained-failure alert (10–15 minutes): ALG6 molecular genetics platforms, family cascade evaluation platforms, prenatal genetic testing platforms, neurodevelopmental assessment platforms, ketogenic diet monitoring systems, ophthalmological assessment platforms, physical and occupational therapy records, and ALG6-CDG registry data transfer platforms.
30-day advance warning: SSL certificates across all domains.
Vigilmon's multi-region monitoring confirms ALG6-CDG platform availability from the metabolic medicine centers, pediatric and adult neurology programs, neurophysiology departments, molecular genetics laboratories, hematology services, hepatology departments, ophthalmology departments, dietetics services, neurodevelopmental assessment centers, and CDG registry coordination programs that serve the ALG6-CDG population.
Status Page for ALG6-CDG Care Team Communication
A real-time status page gives metabolic medicine teams processing transferrin CDG analysis and ALG6 enzyme activity results, pediatric and adult neurologists managing epilepsy and ataxia, neurophysiologists reporting routine and video-EEG telemetry, hematologists managing the paradoxical coagulopathy and anti-epileptic drug-coagulopathy interactions, molecular genetics teams performing ALG6 sequencing and family cascade evaluations, hepatologists monitoring liver disease and hepatotoxic drug safety, ophthalmologists managing strabismus and retinal disease, dietitians managing nutritional support and ketogenic diet in drug-refractory epilepsy, physical and occupational therapists managing hypotonia and ataxia, speech-language pathologists managing communication and dysphagia, neurodevelopmental specialists tracking cognitive trajectory and educational placement, and families managing seizure diaries, anti-epileptic drugs, and illness protocols at home — immediate platform visibility without requiring inbound IT support contact.
Include the status page URL in ALG6-CDG clinic epilepsy emergency protocols, neurophysiology department EEG downtime procedures, hematology coagulopathy management backup plans, and anti-epileptic drug toxicity emergency response procedures.
Vigilmon Setup for ALG6-CDG Tech Platforms
A practical starting configuration:
| Monitor | Check Interval | Alert Channel | |---------|----------------|---------------| | Authentication | 1 min | Slack + PagerDuty (24/7) | | EEG (routine and acute seizure characterization) | 1 min | Slack + PagerDuty (clinical hours) | | Video-EEG telemetry (seizure semiology documentation) | 1 min | Slack + PagerDuty (clinical hours) | | Anti-epileptic drug levels (phenytoin, phenobarbital, carbamazepine) | 1 min | Slack + PagerDuty (lab hours) | | Transferrin IEF/MS (CDG diagnosis and monitoring) | 1 min | Slack + PagerDuty (lab hours) | | ALG6 glucosyltransferase enzyme assay (fibroblasts) | 1 min | Slack + PagerDuty (lab hours) | | ALG6 gene sequencing and del/dup analysis | 1 min | Slack + PagerDuty (lab hours) | | Coagulation factors (XI, antithrombin, protein C, S, INR) | 1 min | Slack + PagerDuty (lab hours) | | Platelet function (valproate-associated monitoring) | 1 min | Slack + PagerDuty (lab hours) | | Brain MRI (white matter, cortical, acute events) | 1 min | Slack + PagerDuty (clinical hours) | | Hepatic function (ALT, AST, GGT, albumin — hepatotoxic AED monitoring) | 1 min | Slack + PagerDuty (lab hours) | | Ketogenic diet monitoring (glucose, ketones, lipids) | 1 min | Slack + PagerDuty (clinical hours) | | Ophthalmological assessment (strabismus, retina, visual acuity) | 1 min | Slack + PagerDuty (clinical hours) | | Neurodevelopmental assessment records | 2 min | Slack (clinical hours) | | Ataxia severity rating records | 2 min | Slack (clinical hours) | | Peripheral neuropathy (nerve conduction studies) | 2 min | Slack (clinical hours) | | Physical and occupational therapy records | 2 min | Slack (clinical hours) | | Family cascade molecular testing | 2 min | Slack (lab hours) | | Prenatal and preimplantation genetic testing | 2 min | Slack (business hours) | | ALG6-CDG registry data transfer | 2 min | Slack (business hours) | | SSL: all domains | Daily | Email (30-day warning) |
Getting started:
- Create a free account at vigilmon.online
- Add authentication endpoints at 1-minute intervals with 24/7 alerting
- Configure EEG and video-EEG platforms with immediate clinical-hours alerting — the primary safety monitoring tools for ALG6-CDG patients with epilepsy, where acute seizure characterization during clinical escalation determines anti-epileptic drug selection and status epilepticus management
- Add anti-epileptic drug level monitoring platforms with immediate laboratory-hours alerting — drug level assessment during dose titration, breakthrough seizure evaluation, and toxicity monitoring in patients with concurrent coagulopathy and hepatic disease
- Configure transferrin isoelectric focusing and mass spectrometry platforms with immediate laboratory-hours alerting — the Type I CDG transferrin pattern is the gateway diagnostic step distinguishing CDG syndromes from structural brain malformations and chromosomal disorders
- Add ALG6 glucosyltransferase enzyme assay platforms with immediate laboratory-hours alerting — the glucosyltransferase I functional assay in fibroblasts is the enzyme confirmation test for ALG6-CDG, distinguishing it from PMM2-CDG and other Type I CDG syndromes with identical transferrin patterns
- Configure ALG6 gene sequencing platforms with immediate laboratory-hours alerting for p.Ala333Val founder variant detection, second allele identification, and family cascade initiation
- Add coagulation factor monitoring platforms (factor XI, antithrombin, protein C, protein S, platelet function) with immediate laboratory-hours alerting for the paradoxical coagulopathy and anti-epileptic drug-coagulopathy interaction monitoring
- Configure brain MRI platforms with immediate clinical-hours alerting for white matter and cortical disease characterization and acute event evaluation in patients with epilepsy and coagulopathy
- Add hepatic function monitoring platforms with immediate laboratory-hours alerting for liver disease surveillance and hepatotoxic anti-epileptic drug safety monitoring
- Configure ketogenic diet monitoring platforms with immediate clinical-hours alerting for glucose, ketone, and acid-base monitoring in drug-refractory epilepsy patients on the ketogenic diet
- Add ophthalmological assessment platforms with immediate clinical-hours alerting for strabismus surgical management and retinal disease surveillance
- Configure neurodevelopmental assessment platforms with sustained-failure alerting for cognitive trajectory documentation and educational planning
- Add ataxia rating scale platforms with sustained-failure alerting for cerebellar function monitoring
- Configure peripheral neuropathy monitoring platforms with sustained-failure alerting for nerve conduction study results
- Add family cascade molecular testing platforms with sustained-failure alerting for at-risk sibling presymptomatic diagnosis, with particular attention to p.Ala333Val carrier testing in Irish-American families
- Configure prenatal genetic testing platforms with sustained-failure alerting for reproductive decision support in affected families
- Add ALG6-CDG registry data transfer platforms with sustained-failure alerting
- Enable SSL certificate monitoring across all transferrin CDG analysis, enzyme assay, EEG, AED monitoring, coagulation, neuroimaging, hepatic function, and ketogenic diet platforms
- Add the status page URL to ALG6-CDG clinic epilepsy emergency protocols, EEG downtime procedures, coagulopathy management backup plans, and anti-epileptic drug toxicity emergency response procedures
Conclusion
ALG6-CDG technology platforms are embedded in clinical decisions where EEG platform availability for a pediatric neurologist evaluating a 6-year-old with ALG6-CDG and a 12-minute episode of unresponsiveness, head deviation, and right-arm clonic jerking — when the platform required to report the routine EEG showing multifocal epileptiform discharges with a generalized sharp-wave component superimposed on a diffusely slow background, confirming focal-onset epilepsy with secondary generalization and directing the choice of lamotrigine rather than valproate (the latter avoided in the context of the factor XI deficiency at 34% and antithrombin deficiency at 31% that create hemorrhagic risk with platelet function impairment) is unavailable during the post-event epilepsy evaluation — prevents the epilepsy characterization and drug selection decision that determines the seizure-free outcome; where anti-epileptic drug level monitoring platform availability for the same patient 4 months into lamotrigine therapy presenting with a breakthrough tonic-clonic seizure during a febrile illness — when the platform required to report the lamotrigine level at 2.1 mg/L, below the therapeutic range of 3–15 mg/L, confirming under-dosing relative to the fever-induced glucuronidation acceleration that reduced lamotrigine bioavailability, is unavailable during the emergency assessment — delays the dose escalation that would have prevented the prolonged post-ictal state requiring 72-hour EEG monitoring hospitalization; and where coagulation monitoring platform availability for the same patient evaluated for strabismus surgery — when the platform delivering the antithrombin activity at 28%, protein C at 25%, and factor XI at 31% that require the strabismus surgeon, anesthesiologist, and hematologist to jointly plan perioperative antithrombin concentrate administration and post-operative hemorrhagic risk management is unavailable during the pre-operative assessment — allows the surgery to proceed without hematology-guided perioperative coagulopathy management, increasing the risk of post-operative hemorrhagic complication. A seizure monitoring platform unavailable when EEG characterization is determining anti-epileptic drug selection in a child with ALG6-CDG epilepsy, a drug level monitoring platform down when lamotrigine under-dosing is producing breakthrough seizures during febrile illness, a coagulation monitoring platform unavailable when perioperative hemorrhagic risk management requires antithrombin deficiency documentation — these are not IT incidents. They are clinical crises in the management of a rare CDG syndrome with an epilepsy burden affecting half its patients, a paradoxical coagulopathy that interacts dangerously with the most common anti-epileptic drugs, and a neurodevelopmental monitoring obligation spanning decades in patients with moderate to severe intellectual disability and ataxia.
Uptime monitoring gives ALG6-CDG tech teams the detection capability to identify failures within seconds, trigger immediate clinical downtime procedures, and demonstrate to metabolic medicine centers, pediatric and adult neurology programs, neurophysiology departments, molecular genetics laboratories, hematology services, hepatology departments, ophthalmology departments, ketogenic diet programs, neurodevelopmental assessment centers, and compliance auditors that platform operational reliability matches the seizure monitoring urgency, coagulopathy management complexity, neurodevelopmental surveillance obligations, and multi-system monitoring demands of modern ALG6-CDG care.
Start monitoring your ALG6-CDG care tech platform for free at vigilmon.online — HTTP/HTTPS monitoring, multi-region consensus alerting, SSL certificate monitoring, automatic status page, Slack and webhook alerts. No agent required. No credit card.
Tags: #monitoring #ALG6CDG #CDG #CongenitalDisorderOfGlycosylation #CDGIc #ALG6 #glucosyltransferase #epilepsy #seizures #intellectualDisability #hypotonia #ataxia #coagulopathy #calnexinCalreticulin #glycosylation #transferrinCDG #rareDisease #metabolicDisease #HIPAA #healthtech #digitalhealth #uptime #sre